Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Shibani Nicum
No relevant relationships to disclose
Claire E Brooks
No relevant relationships to disclose
Rose Wharton
No relevant relationships to disclose
Lucy Boyle
No relevant relationships to disclose
Stanley B. Kaye
No relevant relationships to disclose
Charlie Gourley
Research Funding - AstraZeneca
Marcia Hall
No relevant relationships to disclose
Ana Montes
No relevant relationships to disclose
Sarah R Pearson
No relevant relationships to disclose
Patrick Julier
No relevant relationships to disclose
Rachel A Midgley
No relevant relationships to disclose
Anna Schuh
Honoraria - Celgene; GlaxoSmithKline; Roche
Susan J. Dutton
No relevant relationships to disclose